INVESTIGATING DRUG-INDUCED DEMENTIA IN A CNS MPS ASSESSING DEFICITS IN LTP FROM ANTICHOLINERGIC COGNITIVE BURDEN
Kaveena Autar, Maria Grisales, Chelsea Honore, Xiufang Guo, David Morgan, Veronique Michaud, Jacques Turgeon, James Hickman · 2024
Read INVESTIGATING DRUG-INDUCED DEMENTIA IN A CNS MPS ASSESSING DEFICITS IN LTP FROM ANTICHOLINERGIC COGNITIVE BURDEN by Kaveena Autar, Maria Grisales, Chelsea Honore, Xiufang Guo, David Morgan, Veronique Michaud, Jacques Turgeon, James Hickman (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11691038.txt.
Description
Kaveena Autar and seven co-authors grew a tiny human brain model in the lab to test how common drugs can dull thinking. Their system grows stem-cell-derived cortical neurons on electrode arrays and measures long-term potentiation, the strengthening of synapses that underlies learning. The target was anticholinergic burden: many everyday medicines block a key brain chemical, and their combined load is suspected of nudging people toward dementia.
The burden drugs weakened potentiation in a clean dose-response pattern. Caffeine partly reawakened the silenced networks, mimicking its alerting effect in people. An Alzheimer's drug that protects the same chemical restored the deficits, confirming the mechanism. Adding amyloid fragments, the stuff of Alzheimer's plaques, made the drug damage worse, suggesting patients with early disease are most at risk. The authors offer the platform as a way to screen medicines for hidden cognitive costs before they reach patients.
Catalog record
| CREATOR | Kaveena Autar, Maria Grisales, Chelsea Honore, Xiufang Guo, David Morgan, Veronique Michaud, Jacques Turgeon, James Hickman |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |